{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:45:32Z","timestamp":1793749532503,"version":"4.6.1"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.seizure.2022.09.013","type":"journal-article","created":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T11:24:49Z","timestamp":1663413889000},"page":"6-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Sex differences in side effects of antiseizure medications in pediatric patients with epilepsy: A systematic review"],"prefix":"10.1016","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2512-6972","authenticated-orcid":false,"given":"Loretta","family":"Giuliano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Vecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7218-2267","authenticated-orcid":false,"given":"Vincenzo","family":"Mastrangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vania","family":"Durante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Zambrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Cantalupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"La Neve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Ermio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6994-0821","authenticated-orcid":false,"given":"Barbara","family":"Mostacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2022.09.013_bib0001","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)31561-0","article-title":"Sex and gender: modifiers of health, disease, and medicine","volume":"396","author":"Mauvais-Jarvis","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.seizure.2022.09.013_bib0002","first-page":"11","article-title":"Introduzione alla farmacologia di genere","volume":"5","author":"Franconi","year":"2013","journal-title":"G Ital di Farm e Farm"},{"key":"10.1016\/j.seizure.2022.09.013_bib0003","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"48","author":"Soldin","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.seizure.2022.09.013_bib0004","first-page":"109","article-title":"Hypohidrosis-related symptoms in pediatric epileptic patients with topiramate","volume":"52","author":"Kim","year":"2010","journal-title":"Pediatr Int Off J Jpn Pediatr Soc"},{"key":"10.1016\/j.seizure.2022.09.013_bib0005","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/epi.13509","article-title":"Association of HLA genotypes with phenobarbital hypersensitivity in children","volume":"57","author":"Manuyakorn","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2022.09.013_bib0006","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF02337619","article-title":"Effects of carbamazepine and valproate on immunological assessment in young epileptic patients","volume":"12","author":"Lenti","year":"1991","journal-title":"Ital J Neurol Sci"},{"key":"10.1016\/j.seizure.2022.09.013_bib0007","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12185-017-2323-0","article-title":"Decreased platelet count in children with epilepsy treated with valproate and its relationship to the immature platelet fraction","volume":"107","author":"Kurahashi","year":"2018","journal-title":"Int J Hematol"},{"key":"10.1016\/j.seizure.2022.09.013_bib0008","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1177\/0883073811421985","article-title":"Evaluation of subclinical hypothyroidism in ambulatory children with controlled epilepsy on valproate monotherapy","volume":"27","author":"Sahu","year":"2012","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2022.09.013_bib0009","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/00207454.2011.627486","article-title":"Thyroid hormones in children on antiepileptic therapy","volume":"122","author":"Ayg\u00fcn","year":"2012","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.seizure.2022.09.013_bib0010","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.yebeh.2010.12.012","article-title":"Nonalcoholic fatty liver disease in adolescents receiving valproic acid","volume":"20","author":"Verrotti","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2022.09.013_bib0011","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/BF00306271","article-title":"Anti-epileptic therapy and behaviour disturbances in children","volume":"9","author":"Domizio","year":"1993","journal-title":"Childs Nerv Syst"},{"key":"10.1016\/j.seizure.2022.09.013_bib0012","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0140-6736(97)06250-8","article-title":"Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India","volume":"351","author":"Pal","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2022.09.013_bib0013","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0887-8994(99)00151-4","article-title":"Factors associated with behavioral and cognitive abnormalities in children receiving topiramate","volume":"22","author":"Gerber","year":"2000","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2022.09.013_bib0014","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1177\/08830738050200110601","article-title":"Efficacy and safety of topiramate in refractory epilepsy of childhood: long-term follow-up study","volume":"20","author":"Grosso","year":"2005","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2022.09.013_bib0015","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/bmj.39022.436389.BE","article-title":"Side effects of phenobarbital and carbamazepine in childhood epilepsy: randomised controlled trial","volume":"334","author":"Banu","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.seizure.2022.09.013_bib0016","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.pediatrneurol.2014.05.033","article-title":"Effects of topiramate on language functions in newly diagnosed pediatric epileptic patients","volume":"51","author":"Kim","year":"2014","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2022.09.013_bib0017","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/epi.13279","article-title":"Cognitive effects of adjunctive perampanel for partial-onset seizures: a randomized trial","volume":"57","author":"Meador","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2022.09.013_bib0018","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1046\/j.1528-1157.2002.17801.x","article-title":"Visual field constriction in 91 Finnish children treated with vigabatrin","volume":"43","author":"Vanhatalo","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2022.09.013_bib0019","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3346\/jkms.2006.21.4.728","article-title":"Vigabatrin and visual field defects in pediatric epilepsy patients","volume":"21","author":"You","year":"2006","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.seizure.2022.09.013_bib0020","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1528-1167.2008.01961.x","article-title":"Visual fields at school-age in children treated with vigabatrin in infancy","volume":"50","author":"Gaily","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2022.09.013_bib0021","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1167\/iovs.08-3237","article-title":"Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy","volume":"50","author":"Durbin","year":"2009","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.seizure.2022.09.013_bib0022","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/01.wnl.0000471111.65017.4f","article-title":"Vigabatrin retinal toxicity in children with infantile spasms: an observational cohort study","volume":"85","author":"Akula","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2022.09.013_bib0023","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/archdischild-2016-311436","article-title":"Hyperhomocysteinaemia in children receiving phenytoin and carbamazepine monotherapy: a cross-sectional observational study","volume":"102","author":"Chandrasekaran","year":"2017","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.seizure.2022.09.013_bib0024","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s13312-018-1322-4","article-title":"Carnitine deficiency in chinese children with epilepsy on valproate monotherapy","volume":"55","author":"Qiliang","year":"2018","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.seizure.2022.09.013_bib0025","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eplepsyres.2009.04.002","article-title":"The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status","volume":"86","author":"Hamed","year":"2009","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2022.09.013_bib0026","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/epi.12125","article-title":"Risk factors for hyperammonemia in pediatric patients with epilepsy","volume":"54","author":"Yamamoto","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2022.09.013_bib0027","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bcpt.13049","article-title":"Risk factors for valproic acid-induced hyperammonaemia in chinese paediatric patients with epilepsy","volume":"123","author":"Zhu","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.seizure.2022.09.013_bib0028","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/07435800.2012.662663","article-title":"The effects of oxcarbazepine and valproate therapies on growth in children with epilepsy","volume":"37","author":"Cansu","year":"2012","journal-title":"Endocr Res"},{"key":"10.1016\/j.seizure.2022.09.013_bib0029","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.pediatrneurol.2012.12.028","article-title":"Effect of topiramate monotherapy on height in newly diagnosed children with epilepsy","volume":"48","author":"Ford","year":"2013","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2022.09.013_bib0030","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.eplepsyres.2007.11.005","article-title":"Increased oxidative stress in epileptic children treated with valproic acid","volume":"78","author":"Verrotti","year":"2008","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2022.09.013_bib0031","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00381-012-1788-7","article-title":"Plasma leptin, neuropeptide Y, ghrelin, and adiponectin levels and carotid artery intima media thickness in epileptic children treated with valproate","volume":"28","author":"Tokgoz","year":"2012","journal-title":"Childs Nerv Syst"},{"key":"10.1016\/j.seizure.2022.09.013_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-1211(00)00119-4","article-title":"The effects on lipid and apolipoprotein serum levels of long-term carbamazepine, valproic acid and phenobarbital therapy in children with epilepsy","volume":"41","author":"Eir\u00eds","year":"2000","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2022.09.013_bib0033","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s004310050664","article-title":"Serum lipids in epileptic children treated with carbamazepine and valproate","volume":"156","author":"S\u00f6z\u00fcer","year":"1997","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.seizure.2022.09.013_bib0034","first-page":"1151","article-title":"Serum lipid profile in children receiving anti-epileptic drug monotherapy: is it atherogenic?","volume":"19","author":"Tekgul","year":"2006","journal-title":"J Pediatr Endocrinol Metab JPEM"},{"key":"10.1016\/j.seizure.2022.09.013_bib0035","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1017\/S1047951110000697","article-title":"Assessment of low-density lipoprotein oxidation, paraoxonase activity, and arterial distensibility in epileptic children who were treated with anti-epileptic drugs","volume":"20","author":"Yildiz","year":"2010","journal-title":"Cardiol Young"},{"key":"10.1016\/j.seizure.2022.09.013_bib0036","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jpeds.2006.08.015","article-title":"Oxidative stress in children receiving valproic acid","volume":"149","author":"Michoulas","year":"2006","journal-title":"J Pediatr"},{"key":"10.1016\/j.seizure.2022.09.013_bib0037","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1695-4033(03)78091-6","article-title":"Efectos del \u00e1cido valproico sobre el desarrollo sexual","volume":"58","author":"Mart\u00ednez","year":"2003","journal-title":"An Pediatr\u00eda"},{"key":"10.1016\/j.seizure.2022.09.013_bib0038","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1528-1167.2009.02307.x","article-title":"Ghrelin levels are reduced in prepubertal epileptic children under treatment with carbamazepine or valproic acid","volume":"51","author":"Prodam","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2022.09.013_bib0039","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/08830738030180021701","article-title":"Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial","volume":"18","author":"Biton","year":"2003","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2022.09.013_bib0040","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/088307389901400802","article-title":"Risk of excessive weight gain in epileptic children treated with valproate","volume":"14","author":"Novak","year":"1999","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2022.09.013_bib0041","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0887-8994(02)00505-2","article-title":"Valproic acid-associated weight gain in older children and teens with epilepsy","volume":"28","author":"Wirrell","year":"2003","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2022.09.013_bib0042","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.seizure.2003.12.001","article-title":"Changes in body mass index during long-term topiramate therapy in paediatric epilepsy patients\u2013a retrospective analysis","volume":"13","author":"Reiter","year":"2004","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2022.09.013_bib0043","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ejpn.2008.05.005","article-title":"States of serum leptin and insulin in children with epilepsy: risk predictors of weight gain","volume":"13","author":"Hamed","year":"2009","journal-title":"Eur J Paediatr Neurol EJPN"},{"key":"10.1016\/j.seizure.2022.09.013_bib0044","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1177\/0883073808323023","article-title":"Weight gain in children treated with valproate","volume":"24","author":"Sharpe","year":"2009","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2022.09.013_bib0045","first-page":"193","article-title":"[The prevalence of obesity and metabolic syndrome in paediatric patients with epilepsy treated in monotherapy with valproic acid]","volume":"61","author":"Carmona-Vazquez","year":"2015","journal-title":"Rev Neurol"},{"key":"10.1016\/j.seizure.2022.09.013_bib0046","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/ane.12473","article-title":"Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain","volume":"133","author":"Noai","year":"2016","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2022.09.013_bib0047","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.eplepsyres.2016.03.004","article-title":"Weight gain in children on oxcarbazepine monotherapy","volume":"122","author":"Garoufi","year":"2016","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2022.09.013_bib0048","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/000992289903800205","article-title":"Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years","volume":"38","author":"Kafali","year":"1999","journal-title":"Clin Pediatr"},{"key":"10.1016\/j.seizure.2022.09.013_bib0049","first-page":"933","article-title":"Evaluation of bone mineral metabolism in children receiving carbamazepine and valproic acid","volume":"13","author":"Altay","year":"2000","journal-title":"J Pediatr Endocrinol Metab JPEM"},{"key":"10.1016\/j.seizure.2022.09.013_bib0050","first-page":"247","article-title":"Bone mineral status in ambulatory pediatric patients on long-term anti-epileptic drug therapy","volume":"44","author":"Tsukahara","year":"2002","journal-title":"Pediatr Int Off J Jpn Pediatr Soc"},{"key":"10.1016\/j.seizure.2022.09.013_bib0051","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pediatrneurol.2006.03.004","article-title":"Adverse effects of antiepileptic drugs on bone mineral density","volume":"35","author":"Babayigit","year":"2006","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2022.09.013_bib0052","first-page":"703","article-title":"The effects of antiepileptic drugs on the relationships between leptin levels and bone turnover in prepubertal children with epilepsy","volume":"24","author":"Aksoy","year":"2011","journal-title":"J Pediatr Endocrinol Metab JPEM"},{"key":"10.1016\/j.seizure.2022.09.013_bib0053","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2310\/7010.2006.00050","article-title":"Effects of anticonvulsant therapy on vitamin D status in children: prospective monitoring study","volume":"21","author":"Nicolaidou","year":"2006","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2022.09.013_bib0054","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.pediatrneurol.2010.05.013","article-title":"Effect of carbamazepine therapy on vitamin D and parathormone in epileptic children","volume":"43","author":"Misra","year":"2010","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2022.09.013_bib0055","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3349\/ymj.2014.55.2.417","article-title":"Vitamin D levels in children and adolescents with antiepileptic drug treatment","volume":"55","author":"Baek","year":"2014","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.seizure.2022.09.013_bib0056","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/j.1528-1167.2011.03245.x","article-title":"Incidence of kidney stones with topiramate treatment in pediatric patients","volume":"52","author":"Mahmoud","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2022.09.013_bib0057","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1055\/s-0038-1676287","article-title":"High incidence of renal stones in severely disabled children with epilepsy treated with topiramate","volume":"50","author":"Ishikawa","year":"2019","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.seizure.2022.09.013_bib0058","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1824-7288-37-21","article-title":"Renal tubular dysfunction measured by N-acetyl-beta glucosaminidase\/creatinine activity index in children receiving antiepileptic drugs: a randomized controlled trial","volume":"37","author":"Mazaheri","year":"2011","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.seizure.2022.09.013_bib0059","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s10157-017-1472-z","article-title":"Risk factors for sodium valproate-induced renal tubular dysfunction","volume":"22","author":"Koga","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.seizure.2022.09.013_bib0060","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4103\/njcp.njcp_120_18","article-title":"Valproic acid-induced nocturnal enuresis in pediatric patients","volume":"22","author":"Ozan","year":"2019","journal-title":"Niger J Clin Pract"},{"key":"10.1016\/j.seizure.2022.09.013_bib0061","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0920-1211(97)00025-9","article-title":"A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy","volume":"27","author":"Guerreiro","year":"1997","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2022.09.013_bib0062","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2174\/1574886314666190311112710","article-title":"Adverse drug reactions of anti-epileptic drugs in children with epilepsy: a cross-sectional study","volume":"14","author":"Kaushik","year":"2019","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.seizure.2022.09.013_bib0063","first-page":"E60","article-title":"Association between adverse effects and parental beliefs about antiepileptic medicines","volume":"54","author":"Ili\u0107","year":"2018","journal-title":"Med Kaunas Lith"},{"key":"10.1016\/j.seizure.2022.09.013_bib0064","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejpn.2015.12.015","article-title":"Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with lennox-gastaut syndrome: an interim analysis from a multicenter, randomized, active-controlled, open-label study","volume":"20","author":"Arzimanoglou","year":"2016","journal-title":"Eur J Paediatr Neurol EJPN"},{"key":"10.1016\/j.seizure.2022.09.013_bib0065","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/epi.12689","article-title":"Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience","volume":"55","author":"Thome-Souza","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2022.09.013_bib0066","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/j.1528-1167.2008.01589.x","article-title":"Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile","volume":"49","author":"Camposano","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2022.09.013_bib0067","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1055\/s-0034-1387815","article-title":"Zonisamide: pharmacokinetics, efficacy, and adverse events in children with epilepsy","volume":"45","author":"Wallander","year":"2014","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.seizure.2022.09.013_bib0068","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/epi.13712","article-title":"Risk of vigabatrin-associated brain abnormalities on MRI in the treatment of infantile spasms is dose-dependent","volume":"58","author":"Hussain","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2022.09.013_bib0069","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.seizure.2019.05.016","article-title":"Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures - an open-label trial","volume":"71","author":"Ferreira","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2022.09.013_bib0070","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/WNF.0b013e31829a498d","article-title":"Adverse effects of antiepileptic drugs in North Indian pediatric outpatients","volume":"36","author":"Bansal","year":"2013","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.seizure.2022.09.013_bib0071","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1651-2227.1986.tb10291.x","article-title":"Influence of valproic acid on the gonadotropin-releasing hormone test in puberty","volume":"75","author":"Lundberg","year":"1986","journal-title":"Acta Paediatr Scand"},{"key":"10.1016\/j.seizure.2022.09.013_bib0072","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/0024-3205(86)90286-9","article-title":"Pharmacological evidence for a dual GABAergic regulation of growth hormone release in humans","volume":"39","author":"Steardo","year":"1986","journal-title":"Life Sci"},{"key":"10.1016\/j.seizure.2022.09.013_bib0073","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1034\/j.1399-6576.2003.00036.x","article-title":"Gender differences in drug effects: implications for anesthesiologists","volume":"47","author":"Pleym","year":"2003","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.seizure.2022.09.013_bib0074","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1172\/JCI118551","article-title":"Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects","volume":"97","author":"Sinha","year":"1996","journal-title":"J Clin Investig"},{"key":"10.1016\/j.seizure.2022.09.013_bib0075","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1111\/j.1528-1157.1999.tb01599.x","article-title":"Characteristics of a unique visual field defect attributed to vigabatrin","volume":"40","author":"Wild","year":"1999","journal-title":"Epilepsia"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131122002102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131122002102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T02:01:08Z","timestamp":1761012068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131122002102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":75,"alternative-id":["S1059131122002102"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2022.09.013","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sex differences in side effects of antiseizure medications in pediatric patients with epilepsy: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2022.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}